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B
lood pressure (BP) levels in the doc-
tor’s clinic may not always reﬂect
those of daily living, as indicated by
24-h ambulatory or self-monitoring mea-
surements. Simple logic implies that
treatment should be guided by the actual
BP levels, rather than by imprecise clinic
measurements. On average, BP measured
in the clinic is higher than out-of-ofﬁce
BP. This difference occurs in a consider-
able number of patients with white-coat
hypertension (WCH). The issue is com-
plicated, since most studies deﬁne WCH
as an elevated ofﬁce BP in patients with
normal awake ambulatory BP. However,
the “awake” state may not fully reﬂect the
24-h BP load. Average 24-h BP, and par-
ticularly that during sleep, which is more
likely to be higher in subjects with diabe-
tes (1,2), could be elevated in a patient
with normal awake BP. The presence of
abnormal clinic BP in such a patient dis-
closes true hypertension rather than
WCH. Indeed, among 4,121 subjects re-
ferred for ambulatory BP monitoring,
4.5% had isolated abnormal sleep BP
(120/70 mmHg) and normal 24-h BP
(3). Nevertheless, in this presentation, we
assume that the common deﬁnition of
WCHiselevatedclinicreadingswithnor-
mal awake BP.
Assessment of WCH in diabetes is
complicated by the fact that normal BP
measured at the clinic is deﬁned as
130/80 mmHg (as opposed to 140/90
mmHg in the general population),
whereastherearestillnoacceptedthresh-
olds for ambulatory or home-based BP
levels.
Characteristics unique to the white-
coat response in patients with diabetes,
associated prognostic implications, and
the need for treatment are discussed.
PREVALENCE OF WCH IN
DIABETES— The issue of prevalence
is not marginal: we have found that com-
paredwithsubjectswithoutdiabeteswho
were referred for 24-h ambulatory BP
monitoring, those treated for diabetes
were less likely to have WCH (and more
likely to have masked hypertension) (1).
A similar conclusion was arrived at in a
recent Brazilian study where masked hy-
pertension was not only more prevalent
(4), but also associated with a higher rate
of target organ damage (5).
Among a cohort of 3,995 patients re-
ferred to our department for ambulatory
BP monitoring, 343 were being medically
treated for diabetes. They were older,
more obese, and had higher BP, both in
the clinic and by ambulatory monitoring,
despite the increased likelihood of being
treated with medications (1). WCH was
deﬁnedasawakeBPbelow135/85mmHg
in the presence of elevated clinic BP. Its
prevalence was marginally lower among
the subjects with diabetes: 8.5 versus
11.4% among those without diabetes
(odds radio [OR] 0.72 [95% CI 0.48–
1.06]). For comparison, the OR for nor-
mal awake systolic BP among subjects
with diabetes (regardless of clinic BP) was
lower (0.43 [0.32–0.56]).
Lower prevalence of WCH was also
found in a massive multicenter study in
Spain, comprising 12,895 treated hyper-
tensive patients, of whom 2,772 had type
2 diabetes. This study had a greater num-
ber of subjects and comprised more pa-
tientsdiagnosedwithtype2diabetesthan
any other, including most combined
studies (6). Lower prevalence of WCH
among patients with diabetes (0.58
[0.41–0.83]) was also found in a reanal-
ysis of the data in a recent study from
Japan, where 301 of 1,267 subjects had
diabetes (2). Conversely, the prevalence
of WCH was similar among patients with
diabetes and normotensive subjects in a
population-based study from Japan,
where WCH was diagnosed by home-
based BP measurements (7).
Overall, it appears that, in type 2 di-
abetes, the caveat for diagnosis of hyper-
tension may fail to detect masked
hypertension (1), rather than failing to
notice WCH. White-coat response to
measurement of BP by a physician is ac-
companied by tachycardia and most
likely reﬂects a sympathetic reaction (8),
as recently conﬁrmed (9–11). Lower
prevalence of WCH in subjects with type
2 diabetes may be explained by the pres-
ence of autonomic neuropathy and thus
lower reactivity to clinic stress.
Thus, it appears that when subjects
with type 2 diabetes—the “prototype” of
high-risk subjects—have a normal BP re-
corded at the clinic, they are more likely
to have home-based, or ambulatory, hy-
pertension. Indeed, white-coat and
masked hypertension may, in part, reﬂect
“regression toward the mean,” depending
on whether high (WCH) or low (masked
hypertension) levels are recorded at the
clinic (12).
PROGNOSIS OF WCH IN
DIABETES— Resultsofstudiesonthe
prognosis of WCH are somewhat contro-
versial (9,13–20). Although most studies
ﬁnd it to be benign (18), this is not a uni-
versal ﬁnding (9,13–17). The results of
several studies demonstrated that sub-
jects with WCH have similar character-
istics to those of hypertensive patients,
including age, BMI, and metabolic and
sympathetic abnormalities, compared
with normotensive patients (9,10,14–
16).This,inpart,couldbeexplainedby
WCH subjects who have a higher (yet
normal) ambulatory BP than normoten-
sive patients. An example could be the
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zioni) study, where higher ambulatory
BP was associated with such abnormal-
ities, as well as with a higher prevalence
of diabetes (21). Similar ﬁndings ap-
peared in studies of subjects with type 2
diabetes (4,22–24). Even slight BP ele-
vation in high-risk subjects (those with
diabetes) may have prognostic implica-
tions. Patients with WCH among 2,285
subjects treated for hypertension and
referred for 24-h ambulatory BP moni-
toring at our service had signiﬁcantly
elevatedambulatoryBP(althoughinthe
normal range), relative to those with
controlled BP (20). Accordingly, sur-
vival was associated with ambulatory
and not manual BP, even after consider-
ation of confounders including diabetes
(20). Similar ﬁndings were presented in
another study (19) and in a recent meta-
analysis (18).
The 343 diabetic patients from our
cohort of patients referred for ambula-
tory BP monitoring were older, more
obese, and had higher BP both in the
clinic and with ambulatory monitoring,
despite their greater likelihood of being
treated with medications (1). Not sur-
prisingly, their demise was also more
likelytooccurduringfollow-upofupto
14 years: their mortality amounted to
27.9/1,000 patient-years, whereas that
of subjects without diabetes was almost
one-third, at 9.8/1,000 patient-years
(P  0.0001). When we analyzed sur-
vival of patients referred for ambulatory
BPmeasurementsbyaCoxproportional
hazard model (after adjustment for age,
sex, BMI, awake systolic BP, and treat-
ment for hypertension), there was no
inﬂuence by quartiles of the white-coat
effect in subjects without diabetes (Fig.
1). However, a similar analysis in indi-
vidualswithdiabetesfoundasigniﬁcant
(P  0.05) interaction with systolic
white-coat effect quartiles and a sub-
stantially improved survival rate in pa-
tients with diabetes in the highest
systolic white-coat quartile (Fig. 2).
Furthermore, in an analysis of the
white-coat effect as a continuous vari-
able, with adjustments as above, an in-
crease of 1 SD of the systolic white-coat
effect was associated with a signiﬁcant
reductioninthehazardratioformortal-
ity only in subjects with diabetes (Fig.
3). The conclusion from these results is
that taking into account confounding
variables (older age, higher BMI, higher
ambulatory BP, and their greater pro-
pensity to be medically treated for hy-
pertension), diabetic patients with
white-coatBPelevationtendtohaveim-
proved survival. This conclusion is also
supported by the ﬁndings in Japanese
patientswithdiabetes,wherecardiovas-
cular complications were signiﬁcantly
less common in WCH (25).
PERSPECTIVE OF
ANTIHYPERTENSIVE
THERAPY FOR OFFICE-
MEASURED BP IN
SUBJECTS WITH DIABETES
AND WCH— Treatment of WCH in
general is not believed to be beneﬁcial
(9,26–28). Decades ago, it was shown
that casual BP, comprising a supplemen-
tal component that is rather similar to the
Figure 1—Survival of patients referred for
24-h ambulatory BP monitoring according to
quartiles of the white-coat effect (clinic-awake
systolic BP difference) by a Cox proportional
hazards model that is adjusted for age, sex,
BMI, awake systolic BP, and treatment for hy-
pertension (P  0.86).
Figure 2—Survival of patients treated for diabetes who were referred for 24-h ambulatory BP
monitoring,accordingtoquartilesofthewhite-coateffect(clinic-awakesystolicBPdifference)by
a Cox proportional hazards model that is adjusted for age, sex, BMI, awake systolic BP, and
treatment for hypertension (P  0.04).
Figure 3—Mortality hazard ratios associated
with 1-SD increase in the white-coat effect
(clinic-awake systolic BP difference) adjusted
forage,sex,BMI,awakesystolicBP,andtreat-
ment for hypertension (P  0.05).
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prognosis, whereas basal relaxed BP
(similartosleepBP)soundlypredictsout-
come (30).
Moreover, treating WCH may produce
excessive lowering of the ambulatory BP
(28). In the INternational VErapamil SR-
trandolaprilSTudy(INVEST)of22,576hy-
pertensive coronary patients, it was found
that lowering diastolic BP to 83 mmHg
was associated with excess mortality and
coronary events. One-third of subjects with
clinic systolic BP 140 mmHg (some of
whom probably had WCH), and one-third
of those with diastolic BP 80 mmHg
(prone to consequences of such excessive
reduction), had type 2 diabetes (31). Thus,
recommendation for treatment of WCH
may come at a price of harming patients
with diabetes and coronary disease, a com-
mon comorbidity, especially among the
older group that comprises a substantial
section of subjects with type 2 diabetes.
Taking all the aforementioned into
consideration, it is unjustiﬁed, or at least
premature, to treat WCH in diabetes with
antihypertensivetherapy.Deﬁningdiabe-
tes-speciﬁc normal ambulatory BP
thresholds will facilitate management of
the problem in clinical practice.
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